Brief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
29/09/2026 12:05
BRIEF-Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease Sept 29 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:
ALDEYRA THERAPEUTICS ANNOUNCES INTENT TO SUBMIT FORMAL DISPUTE RESOLUTION REQUEST FOR REPROXALAP TO TREAT DRY EYE DISEASE
ALDEYRA THERAPEUTICS - TO SUBMIT FORMAL DISPUTE RESOLUTION REQUEST TO FDA FOR REPROXALAP
ALDEYRA THERAPEUTICS - FDRR SUBMISSION AND FDA MEETING EXPECTED IN Q4 2026
ALDEYRA THERAPEUTICS - FDRR TO APPEAL MARCH 16, 2026 COMPLETE RESPONSE LETTER DENYING NDA FOR REPROXALAP
Source text: ID:nBw1vCnlLa
Further company coverage: ALDX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora